

DMD #58602

**Evaluation of Calibration Curve-based Approaches to Predict Clinical Inducers and Non-inducers of CYP3A4 with plated human hepatocytes**

J. George Zhang, Thuy Ho, Alanna L. Callendrello, Robert J. Clark, Elizabeth A. Santone, Sarah Kinsman, Deqing Xiao, Lisa G. Fox, Heidi J. Einolf and David M. Stresser

*Corning Gentest Contract Research Services, Corning Life Sciences, Woburn, MA, USA (J.G.Z, T.H., A.L.C., R.J.C., E.A.S., S.K., D.X., L.G.F., D.M.S); Novartis Institutes for Biomedical Research, East Hanover, NJ, USA (H.J.E.)*

DMD #58602

**Running Title:** Prediction of CYP3A4 induction using Calibration Curves

**Correspondence to:** George Zhang, Ph.D., Corning Gentest Contract Research Services,  
Corning Life Sciences, 6 Henshaw Street, Woburn, MA. Phone: 781-938-2550; Email:  
zhangjg@corning.com

**Text Pages:** 21

**Tables:** 6

**Figures:** 8

**References:** 43

**Abstract** (words): 248

**Introduction** (words): 550

**Discussion** (words): 1500

**Abbreviations:** AUC, area under curve; CI, confidence interval;  $C_{\max-t}$ , total systemic plasma concentration;  $C_{\max-u}$ , unbound systemic plasma concentration; CYP, cytochrome P450; DDI, drug-drug interaction;  $EC_{50}$ , the concentration achieving 50% of the maximum response; EMA, European Medicines Agency;  $E_{\max}$ , the maximum response;  $E_{\min}$ , baseline of the dose-response curve; FDA, Food and Drug Administration;  $F_2$ , the concentration causing 2-fold increase from baseline of the dose-response curve;  $f_{m, CYP3A}$ , fraction metabolized, CYP3A; GMFE; geometric mean fold error; PBPK, physiologically-based pharmacokinetic models; PC, positive control;  $R^2$ , correlation coefficient;  $R_3$ , a term indicating the amount of CYP induction in the liver, expressed as a ratio between 0 and 1; RMSE, root mean square error; RIS, relative induction score; RT-PCR, real-time, reverse transcription polymerase chain reaction

DMD #58602

**ABSTRACT**

Cytochrome P450 (CYP) induction is often considered a liability in drug development. Using calibration curve-based approaches, we assessed the induction parameters  $R_3$ , relative induction score (RIS),  $C_{\max}/EC_{50}$  and  $AUC/F_2$ , derived from concentration-response curves of CYP3A4 mRNA and enzyme activity data *in vitro*, as predictors of CYP3A4 induction potential *in vivo*. Plated cryopreserved human hepatocytes from three donors were treated with 20 test compounds, including several clinical inducers and non-inducers of CYP3A4. After the two day treatment, CYP3A4 mRNA levels and testosterone 6 $\beta$ -hydroxylase activity were determined by RT-PCR and LC-MS/MS analysis, respectively. Our results demonstrated a strong and predictive relationship between the extent of midazolam AUC change in human and the various parameters calculated from both CYP3A4 mRNA and enzyme activity. The relationships exhibited with non-midazolam *in vivo* probes, in aggregate, were unsatisfactory. In general, the models yielded better fits when unbound rather than total plasma  $C_{\max}$  was used to calculate the induction parameters, as evidenced by higher  $R^2$  and lower RMSE and GMFE. With midazolam, the  $R_3$  cut-off value of 0.9, as suggested by FDA guidance, effectively categorized strong inducers, but was less effective in classifying mid-range or weak inducers. This study supports the use of calibration curves generated from *in vitro* mRNA induction response curves to predict CYP3A4 induction potential in human. With the caveat that most compounds evaluated here were not strong inhibitors of enzyme activity, testosterone 6 $\beta$ -hydroxylase activity was also demonstrated to be a strong predictor of CYP3A4 induction potential in this assay model.

DMD #58602

## Introduction

The potential for new drug candidates to exhibit drug-drug interactions (DDI) is a significant concern during the drug development process. Because metabolism by cytochrome P450 enzymes (CYP) is often a major elimination pathway, small-molecule drug candidates are evaluated for CYP inhibition or induction at various stages of development. CYP3A4 comprises 15% to 30% of hepatic P450 content (Shimada et al. 1994; Ohtsuki et al, 2012) and is estimated to account for about half of oxidations in drugs undergoing P450-mediated clearance (Wienkers and Heath, 2005). Therefore, this enzyme is critical to evaluate as a mediator of DDI.

Prediction of human DDI based on *in vitro* data is another important goal during the early stages of drug development. Outcomes of these predictions may ultimately determine whether clinical DDI studies are conducted. Various models and frameworks have been proposed for induction prediction and these have been recently reviewed (Einolf et al. 2013; Almond et al. 2009; Fahmi and Ripp 2011). These include calibration curve-based approaches, mathematical or mechanistic static models, and physiologically-based pharmacokinetic (PBPK) models. Calibration curve-based models can be developed by comparing the observed clinical change in AUC of a probe substrate drug (such as midazolam for CYP3A4) for a set of known inducers/non-inducers of the enzyme of interest, with various *in vitro* induction potency parameters such as relative induction score (RIS) (Ripp et al. 2006), AUC/F<sub>2</sub> (Kanebratt and Andersson 2008), or C<sub>max</sub>/EC<sub>50</sub> (Fahmi and Ripp 2011) obtained from specific lots (donors) of cryopreserved hepatocytes. These models, as well as others (Kato et al. 2005; Shou et al. 2008, Fahmi et al. 2009), can be used to evaluate induction potential and risk of a clinical DDI. Recent guidance from the FDA (2012) and EMA (2013) suggest options for evaluating induction potential, ranging from simple, conservative

## DMD #58602

models (“ $R_3$ ” and a predefined fold-induction threshold) to more complex models as mentioned earlier (e.g. mechanistic static models, PBPK models, RIS). Both guidance documents advocate use of mRNA data, obtained using human hepatocytes. In addition, the documents generally recommend using donor lots that have been previously characterized with a sufficient number of clinical inducers and non-inducers (the EMA basic method being the exception).

Several *in vitro* test systems have been used for assessment and prediction of CYP3A4 induction potential in human by new drug candidates. These systems include primary cultures of cryopreserved human hepatocytes (McGinnity et al. 2009, Fahmi et al. 2010, Shou et al. 2008), human hepatocyte-like cell lines such as Fa2N-4 (Ripp et al. 2006; McGinnity et al. 2009), HepaRG (Kanebratt and Andersson 2008, McGinnity et al. 2009) and more recently a stably-expressed human PXR cell line derived from HepG2 (Fahmi et al. 2012). To date, human hepatocyte cultures have been considered the gold standard for *in vitro* induction assessment and are currently “preferred” by regulatory agencies.

The present work describes a direct comparison of several induction parameters (RIS,  $R_3$ ,  $C_{\max}/EC_{50}$ , and  $AUC/F_2$ ) generated with a set of clinical inducers and non-inducers using human hepatocytes as *in vitro* system, to predict the *in vivo* CYP3A4 induction potential using a calibration curve. In this approach, calibration curves were constructed by plotting various parameters versus the change in clinical probe AUC of observed *in vivo*. The evaluations were conducted using endpoints of mRNA and testosterone 6 $\beta$ -hydroxylase activity generated using either total or unbound plasma  $C_{\max}$  in the models.

## Materials and Methods

**Materials and Reagents.** A set of twenty compounds comprised primarily of clinical inducers and non-inducers were evaluated *in vitro* at concentrations selected based on previous publications (Ripp et al., 2006; Kanebratt and Andersson 2008; McGinnity et al., 2009; Fahmi et al., 2010) (Table 1) and experience within this laboratory. Dimethyl sulfoxide (DMSO), testosterone, acetonitrile, ethanol, and all test drugs were purchased from Sigma-Aldrich (St. Louis, MO) and were of the highest grade available. Inducible cryopreserved human hepatocytes, Corning<sup>®</sup> hepatocyte culture medium, 6 $\beta$ -hydroxytestosterone, 6 $\beta$ -hydroxytestosterone-[D<sub>7</sub>], Corning<sup>®</sup> high viability cryohepatocyte recovery kits, and collagen type I-coated 96-well plates were obtained from Corning Life Science (Tewksbury, MA). Gentamicin was obtained from Lonza (Walkersville, MD). Fungizone<sup>®</sup>, L-glutamine and D-phosphate buffered saline were from Gibco (Grand Island, NY). The RNeasy 96 kit and DNase I were from Qiagen (Valencia, CA). Reverse transcription kit, two-step TaqMan<sup>®</sup> PCR Master Reaction Mix, primers/probes were obtained from Applied Biosystems (Foster City, CA).

**Human Hepatocyte Culture and Treatment.** Inducible cryopreserved human hepatocytes (Lots 295, 312, and 318) were rapidly thawed and plated at a density of  $0.6 \times 10^6$  viable cells/mL (100  $\mu$ L/well) in collagen type-I-coated 96-well plates using high viability cryohepatocyte recovery kits. After approximately 4 hours, the plating medium was replaced with 100  $\mu$ L of hepatocyte culture medium supplemented with 2 mM L-glutamine, 50  $\mu$ g/mL gentamicin, and 0.75  $\mu$ g/mL fungizone, and the cultures were maintained overnight. Hepatocyte cultures were treated for two days with 0.1% DMSO (negative control) and test drugs at eight concentrations each except for primaquine, methotrexate, and digoxin, for which three or four concentrations

## DMD #58602

were tested. All incubations were performed in triplicate. The test concentration range is shown in Table 2.

***In Situ* CYP3A4 Activity Measurement.** The testosterone 6 $\beta$ -hydroxylase activity assay was performed essentially as described by Zhang et al (2010). Briefly, after treatment, hepatocyte cultures were washed with culture medium and incubated with 100  $\mu$ L of culture medium containing CYP3A4 probe substrate testosterone at a concentration of 200  $\mu$ M for 30 min. The reactions were stopped by combining an aliquot from each well with acetonitrile containing internal standard 6 $\beta$ -hydroxytestosterone-[D<sub>7</sub>]. The amount of metabolite formed was determined by LC-MS/MS using an API-4000 mass spectrometer. The culture plates were stored at - 80 °C until total RNA isolation.

**Determination of Test Drug Concentrations in Incubation Medium.** At the end of the second day of treatment, the incubation medium from lot 295 was collected and combined with acetonitrile containing internal standard labetalol. The relative concentrations of test drug remaining in the incubation medium were quantitated by LC-MS/MS using an API-4000 mass spectrometer.

**Total RNA Isolation and Real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) Analysis.** Total RNA was isolated from cells using the RNeasy<sup>®</sup> 96 kit according to instructions provided by the manufacturer. The mRNA expression for CYP3A4 and the house keeping gene  $\beta$ -actin was determined by Taqman<sup>®</sup> RT-PCR methods using the two-step assay protocol. First, a reverse transcription (RT) assay was performed using a GeneAmp<sup>®</sup> PCR System 9700 (Applied Biosystems) with equal volume of total RNA and the RT master mixture. For the PCR assay, a PCR master mixture of reagents was prepared and a 20  $\mu$ L aliquot of the

## DMD #58602

master mixture was transferred to a 96-well optical reaction plate, followed by the addition of 5  $\mu\text{L}$  of acquired *c*DNA to the appropriate wells. The PCR amplification was performed and the transcription was determined using an ABI 7300 Real Time PCR System.

**Data Calculation.** The test drug concentrations ( $\mu\text{M}$ ) remaining in the incubation medium after the two day treatment and the catalytic activity for CYP3A4 in hepatocytes were calculated using standard curves. The fold induction for activity data was calculated as follows: (enzyme activity of test drug)/(mean of enzyme activity of negative control). The fold induction for mRNA data was determined using the calculation of  $2^{-\Delta\Delta\text{CT}}$  (Livak and Schmittgen, 2001). Percentage of positive control response for both activity and mRNA was calculated as follows: (mean of observed maximal fold-1)/(mean of observed maximal fold by rifampicin-1).

**Curve Fitting.** To estimate  $\text{EC}_{50}$ ,  $E_{\text{max}}$ , and  $F_2$  values, concentration-response fold induction data were fitted to a Sigmoid dose-response one site fit model (4 Parameter Logistic Model; Model 205) with XLfit™ (ID Business Solutions, Emeryville, CA) according to equation 1:

$$\text{Induction response}(\text{fold}) = E_{\text{min}} + \left( \frac{E_{\text{max}} - E_{\text{min}}}{1 + \left(\frac{\text{EC}_{50}}{C}\right)^d} \right) \quad (1)$$

where  $E_{\text{min}}$  is the baseline of the curve,  $E_{\text{max}}$  is the maximum effect,  $\text{EC}_{50}$  is the concentration achieving 50% of  $E_{\text{max}}$ ,  $d$  is the slope of the curve, and  $C$  is the drug concentration. An additional parameter,  $F_2$ , which is the drug concentration that causes a 2-fold increase of  $E_{\text{min}}$  was also calculated. The curve fitting was conducted using the following acceptance criteria and conditions: 1) data points were excluded from curve fitting when toxicity, insolubility, and inhibition (enzyme activity only) were apparent or when the coefficient of variation of replicate



## DMD #58602

values was >40% after removing the offending outlier in the original set of triplicate samples); 2) curve fitting data were not used when  $R^2$  of the fit was <0.85; 3) when no apparent plateau was observed after the above mentioned conditions were taken into consideration, the  $E_{\max}$  was constrained to the observed maximal fold to prevent extrapolation of the curve fit beyond measured data, and  $EC_{50}$  was then obtained from the fitted curves. 4)  $EC_{50}$  and  $E_{\max}$  were determined only when fold induction was at least 1.4-fold and the response was concentration-dependent.

The RIS and “ $R_3$ ” values were calculated according to equations 2 and 3, according to the EMA (2013) and FDA (2012) guidance documents, respectively.

$$RIS = \frac{E_{\max} \times [I]}{EC_{50} + [I]} \quad (2)$$

$$R_3 = \frac{1}{\left( \frac{1 + d \times E_{\max} \times [I]}{EC_{50} + [I]} \right)} \quad (3)$$

Where  $[I]$  is total or unbound systemic plasma  $C_{\max}$ ,  $d$  is a scaling factor assumed to be 1 (FDA draft guidance, 2012). Although  $R_3$  as defined in FDA guidance does not permit use of unbound  $C_{\max}$  as the value of  $[I]$ , as part of our investigation, we elected to examine the effect of both total and unbound  $C_{\max}$  on model outcomes.

The  $C_{\max}$  (total and unbound)/ $EC_{50}$  and  $AUC/F_2$  were also calculated, where  $AUC$  is the *in vivo* exposure of the interacting drug, represented by the area under the plasma concentration over time course (Table 3).

## DMD #58602

**Preparation of Calibration Curves.** A set of nine clinical inducers and clinical non-inducers with known midazolam AUC changes after single dosing and clinical pharmacokinetic data was used for the preparation of calibration curves. The compounds included three strong inducers: rifampicin (with four clinical study data points), phenytoin, and carbamazepine; four moderate/weak inducers: troglitazone, terbinafine, pleconaril, and pioglitazone; and two clinical non-inducers nifedipine and clotrimazole (Table 3, as indicated with asterisks). Flumazenil was excluded from the calibration curves because very weak induction was observed in only one of the three donors (mRNA only) and its extremely low  $C_{\max}$  would have yielded a data point far removed from the range of the other points on the calibration curve. The remaining interacting drugs examined here were not used to generate the calibration curves. This is because we used only those compounds where associated clinical data was obtained with the well-established CYP3A4 probe midazolam as the victim drug (see Table 3). *In vitro* data generated for those compounds with non-midazolam clinical data were then evaluated against the curve generated with the aforementioned nine compounds. The calibration curves were constructed with the observed midazolam AUC change against calculated induction parameters ( $RIS$ ,  $R_3$ ,  $C_{\max}/EC_{50}$  and  $AUC/F_2$ ) using equation 4:

$$\% \text{ AUC change} = A + \left( \frac{B - A}{1 + \left(\frac{C}{x}\right)^d} \right) \quad (4)$$

where A is the baseline of the curve constrained to 0%; B is the maximum AUC change constrained to  $\leq 100\%$ , C is the values of induction parameters “x” ( $RIS$ ,  $R_3$ ,  $C_{\max}/EC_{50}$  and  $AUC/F_2$ ) achieving 50% of AUC change and  $d$  is the slope of the curve. The cut-off values for a

## DMD #58602

positive inducer were defined as the induction parameter values leading to a 20% decrease in predicted midazolam AUC change (FDA 2012). The analysis included determination of the 95% confidence interval (CI) for the cut-off values (95% probability that the predicted cut-off values will occur) and correlation coefficient ( $R^2$ ) for goodness of fit. Statistical parameters were determined using the Statistics Designer function with XLfit™ software.

**Comparison of model predictability.** To compare the prediction accuracy of each model, the root mean square error (RMSE) was calculated as described in equation (5), with greater accuracy being shown by the lower RMSE. The fold changes of predicted DDI and the observed DDI were calculated as  $AUC_{\text{induced}}/AUC_{\text{control}}$ . The bias of the prediction models was determined by the geometric mean fold error (GMFE) in equation (6), which weighs over- and under-predictions equally. The lowest GMFE value would represent the lowest prediction bias.

$$\text{RMSE} = \sqrt{\frac{\sum (\text{predicted DDI} - \text{observed DDI})^2}{\text{number of predictions}}} \quad (5)$$

$$\text{GMFE} = 10^{\frac{\sum \left| \log \left( \frac{\text{predicted DDI}}{\text{observed DDI}} \right) \right|}{\text{number of predictions}}} \quad (6)$$

## Results

**Concentration-dependent Induction Response of CYP3A4 mRNA and Activity in Human Hepatocytes.** Hepatocytes from lots 295 (aged 41, female and Caucasian), 312 (aged 56, male and Caucasian) and 318 (aged 58, male and African American) were treated for two days with a medium change and compound replenishment after 24 hours. Both CYP3A4 mRNA levels and catalytic activities were measured. The parameters  $EC_{50}$ ,  $E_{max}$ , and  $F_2$  were determined from the concentration-response curves and % of positive control response was also determined. Overall,  $EC_{50}$  values obtained from both CYP3A4 mRNA and enzyme activity were similar (e.g. within 3-fold) within and between donors, with some notable exceptions (Tables 1 and 2). For example,  $EC_{50}$  for rifampicin was 0.12 and 0.18 for mRNA and enzyme activity, respectively for lot 295, but was 1.4  $\mu$ M and 1.1  $\mu$ M for same endpoints respectively for lot 312.  $E_{max}$  values obtained from mRNA data, in general were greater than those from the activity results. The weak clinical inducers sulfinpyrazone and probenecid produced a potent induction response of CYP3A4 mRNA and/or activity and the response did not reach plateau at the highest concentration within any of the lots (data not shown). Flumazenil caused no induction for both mRNA and activity in lots 295 and 318, however, a slight induction response for CYP3A4 mRNA was observed in lot 312 at the high end of the concentration-response curve. As expected, most compounds previously shown to be inducers *in vivo* and *in vitro* caused a greater than 2-fold induction over vehicle control and exhibited concentration-dependence, the criteria to demonstrate a positive

## DMD #58602

induction result as described in the EMA guidance (2013). A few moderate and/or weak clinical inducers failed to reach these cut-off values for either mRNA or activity for some of these three lots of hepatocytes, such as pleconaril and pioglitazone. Quinidine at the concentration range of 0.11-250  $\mu\text{M}$  caused an induction of CYP3A4 mRNA in two of the 3 lots, but not for enzyme activity for all lots. No induction of CYP3A4 mRNA and activity was observed for primaquine, methotrexate, and digoxin at the concentrations tested in any of the three lots.

**Comparison of Calibration Curves for RIS,  $R_3$ ,  $C_{\text{max}}/EC_{50}$ , and AUC/ $F_2$ .** To examine the relationship between induction data generated *in vitro* and data observed in clinical studies (Tables 3), the RIS,  $R_3$ , and  $C_{\text{max}}/EC_{50}$  values were calculated based on both total and unbound  $C_{\text{max}}$  (Supplemental Tables 1-3, Table 5). The calibration curves were then prepared with the % observed AUC changes of midazolam as a function of parameters RIS,  $R_3$ ,  $C_{\text{max}}/EC_{50}$ , and AUC/ $F_2$  as shown in Figures 1-4 (see Supplemental Figures 1-8 for lots 312 and 318). The proposed cut-off values corresponding to a 20% of predicted midazolam AUC change *in vivo*, 95% confidence interval for the cut-off values, and correlation coefficient  $R^2$  for the calibration curves are summarized in Table 4. Overall, excellent correlation between the induction parameters and observed midazolam AUC changes was obtained with the choice of model with reasonable 95% confidence intervals and  $R^2$  values (0.84-0.995 for mRNA and 0.78-0.99 for activity). Cut-off values were within 3-fold for both mRNA and activity across all three lots for RIS,  $R_3$ , and  $C_{\text{max}}/EC_{50}$ . Relative to other parameters, the cut-off values for AUC/ $F_2$  appeared to vary more across all three lots of hepatocytes.

**Assessment of  $R_3$  Cut-off Value in Prediction of CYP3A4 Inducers.** The  $R_3$  values for each interacting drug were calculated based on both total and unbound  $C_{\text{max}}$  and are presented in Table

## DMD #58602

5. These values were compared with 0.9, a cut-off value for a likely inducer *in vivo* as proposed in the FDA draft guidance (2012). As shown in Table 5,  $R_3$  values calculated with both  $C_{\max-t}$  and  $C_{\max-u}$  classified the strong clinical inducers well, but were less accurate in categorizing mid-range or weak inducers. For example, using  $C_{\max-t}$ , the calculated  $R_3$  values for some of clinical non-inducers such as nifedipine, rosiglitazone, omeprazole, and quinidine were  $<0.9$ , resulting in false positive assignments. In contrast,  $R_3$  values calculated based on  $C_{\max-u}$  were  $>0.9$  for some moderate and weak inducers such as troglitazone, terbinafine, pleconaril and pioglitazone, leading to false negative assignments. This was true of all 3 donors regardless of using mRNA or activity as the endpoint.

**Predicted AUC Changes using the Calibration Curves.** Using the constructed calibration curves, the AUC changes for 16 interacting drugs were predicted from all three lots and compared with the observed AUC changes (Figures 5-7, Supplemental Tables 4-7). As expected, the predicted AUC changes were close to fitted values for the nine interacting drugs with midazolam as the victim drug, although a slight over-prediction was observed for troglitazone and terbinafine using  $RIS$  and  $R_3$ , calculated based on  $C_{\max-t}$  (both activity and mRNA) in some of these lots. The correlation plots between the observed and predicted midazolam AUC changes for three hepatocyte lots were prepared for all induction parameters (Figures 5-7). As anticipated, a strong correlation ( $R^2 = 0.85-0.97$ ) for both mRNA and activity was obtained with the observed AUC changes, regardless of the parameters used. No obvious difference in the robustness of the prediction in midazolam AUC changes was observed using the mRNA versus the activity data. The prediction accuracy and bias for each model were analyzed by RMSE and GMFE using a set of data from both three lots and a single lot. Table 6 shows similar GMFE and RMSE values calculated from this set of three lots for the different prediction methods

DMD #58602

using mRNA or activity as the measured end point. RMSE and GMFE analysis from a single lot provided similar results (data not shown). We found that the correlation was largely improved for all parameters (RIS,  $R_3$ , and  $C_{\max}/EC_{50}$ ) for both mRNA and activity ( $R^2 > 0.94$ ) when using  $C_{\max-u}$ . Consistent with these observations, lower RMSE and GMFE values were obtained when using  $C_{\max-u}$  instead of  $C_{\max-t}$  in the prediction methods (Table 6). No apparent correlation was observed between the observed midazolam or non-midazolam AUC changes and % of positive control response for both activity and mRNA for all three lots ( $R^2 = 0.13-0.41$ ) (Figure 8).

The prediction for the interacting drugs with non-midazolam victim drugs was also conducted with these calibration curves. Weak correlations between the observed and predicted non-midazolam AUC changes for three hepatocyte lots for all induction parameters were found (Figures 5-7) ( $R^2 < 0.40$ ). However, parameters predicted clinical non-inducers reasonably well except for quinidine where a significant over-prediction (32%-93% midazolam AUC change) was found using RIS,  $R_3$ , and  $C_{\max}/EC_{50}$ , generated from mRNA data based on  $C_{\max-u}$  for lot 295 and 312. However, no induction was predicted with AUC/ $F_2$  from both mRNA and activity data for quinidine across all three lots. For moderate/weak inducers, the AUC change for non-midazolam drugs was predicted with varied accuracy. In general, the prediction accuracy was lower and bias was greater in the prediction of the AUC change of CYP3A substrates that were not midazolam. This is evident in the lower RMSE and GMFE values for midazolam trials, as shown in Table 6. In a few cases, either over- or under-prediction was also observed for the *in vivo* AUC changes of nifedipine by phenobarbital, alprazolam by carbamazepine, simvastatin by troglitazone and pioglitazone, depending on parameters and hepatocyte lots (Supplemental Tables 4-7). Significant over-prediction was consistently found for the AUC changes of R-warfarin by sulfinpyrazone (22% observed AUC change vs 59%-94% predicted midazolam

DMD #58602

AUC change) and of carbamazepine by probenecid (20% observed AUC change versus 70%-94% predicted midazolam AUC change), with all parameters for both activity and mRNA across all lots except for AUC/F<sub>2</sub> for lot 318 (Supplemental Tables 4-7).

**Concentration of test compounds in the medium.** The results of such testing in the present study are shown in Supplemental Table 8 for lot 295. Within this set of compounds, concentrations ranged from close to nominal to well below nominal.



## DMD #58602

### Discussion

In this study, model compounds were evaluated for CYP3A4 induction in human hepatocytes and calibration curves constructed to predict responses *in vivo*. As expected, we observed notable inter-donor differences in  $EC_{50}$  and  $E_{max}$  values (e.g. rifampicin  $EC_{50}$  values), which supports regulatory agency guidance recommending calibration of hepatocyte donors for response with a set of inducers and non-inducers. Using resulting calibration curves, inducers were predicted with variable accuracy, whereas non-inducers were generally well-predicted.

Isolated false positive and false negative outcomes were observed. For example, phenobarbital was predicted as a non-inducer with the victim drug nifedipine when the calibration curves of total  $C_{max}/EC_{50}$  from the enzyme activity and/or mRNA data were used (lots 295 and 312). As phenobarbital is a clinical inducer, these results suggest evaluating multiple parameter endpoints would be conservative. Quinidine was also incorrectly classified as an *in vivo* inducer when mRNA was used as the predictor in the RIS,  $R_3$ , and  $C_{max}/EC_{50}$  calibration curve models obtained based on  $C_{max-u}$  with donors 295 and 312. This outcome was attributable to the concentration-dependent induction response of CYP3A4 mRNA, but not activity. Quinidine has been classified as a moderate CYP3A4 inhibitor *in vivo* (Isoherranen et al. 2012) suggesting any induction *in vivo* could be masked. These data highlight the value of acquiring enzyme activity results to help one consider additional, more complex models. For example, the “net-effect” model (Fahmi et al, 2009) incorporates parameters of competitive and time-dependent inhibition that may provide a more informed prediction of clinical DDI.

Our data also suggest that midazolam calibration curves may over-predict AUC changes of non-midazolam victim drugs for weak/moderate inducers, as evidenced by higher midazolam AUC

## DMD #58602

change compared to those obtained with other victim drugs. This is illustrated with predictions of alprazolam AUC change by carbamazepine and simvastatin AUC change by pioglitazone and troglitazone (Table 3, Supplemental Tables 4-7). Similarly, significant over-prediction of *in vivo* response using the midazolam curve was found for sulfinpyrazone and probenecid compared to the observed responses with victim drugs, R-warfarin and carbamazepine. This finding was consistent for all three hepatocytes lots with all modeled induction parameters with exception of AUC/F<sub>2</sub> for lot 318, regardless of activity or mRNA endpoint. Fahmi et al (2012) also reported an over-prediction for sulfinpyrazone using midazolam-RIS calibration curves in DPX2 cells. As midazolam exhibits a very high  $f_{m, CYP3A}$ , it is likely more susceptible to CYP3A4 induction than victim drugs (e.g. R-warfarin) cleared by additional pathways (Ripp et al. 2006; Xu et al. 2011). These findings underscore the use of midazolam as a preferential and sensitive clinical probe for DDI investigations. Notably, two clinically weak inducers, pioglitazone and pleconaril failed to always reach the 2-fold minimum induction response *in vitro* that would classify a compound as an inducer according to EMA guidance. However, this criterion was met for one or more of the other donors underscoring the value of using 3 donors in the standard test.

All calculated induction parameters incorporated *in vivo* total or unbound plasma concentrations of the interacting drugs. Regulatory guidance from the EMA (2013) and FDA (2012) recommend that  $C_{\max-u}$  be used for RIS calculation and  $C_{\max-t}$  for the R<sub>3</sub> calculation, respectively. Our results showed that the AUC changes were reasonably well-predicted when using either  $C_{\max-t}$  or  $C_{\max-u}$  to calculate parameters and was the case for both mRNA and enzyme activity. However, use of  $C_{\max-u}$  resulted in a better correlation between observed and predicted midazolam AUC change (Figures 5-8) with an improved accuracy and precision of predicting the DDI, as RMSE and GMSE were lower (Table 6). These observations are consistent with a previous report (Ripp

## DMD #58602

et al. 2006). Conversely, Fahmi et al (2012) demonstrated that use of total systemic drug concentration in a RIS evaluation resulted in significant improvement in DDI correlations in DPX2 cells, possibly attributable to inclusion of 10% serum in the incubation medium that likely affected the free-fraction in the medium.

The FDA draft guidance (2012) indicates that an investigational drug is likely to be a CYP inducer when the calculated  $R_3$  value is below 0.9. We showed that  $R_3$  cut-off values predicting a 20% midazolam AUC change (e.g. a DDI) were much lower than 0.9 (ranging from 0.44 to 0.65 for CYP3A4 mRNA as well as enzyme activity, across the three lots). Accordingly, we observed a relatively high rate of false positives (e.g. up to 50% exhibited  $R_3 < 0.9$ ). When  $R_3$  values were calculated using  $C_{\max-u}$ , we found several false negative outcomes (Table 5). These data indicate that the 0.9 cut-off value along with the prescribed use of  $C_{\max-t}$  proposed by the FDA is conservative. In our evaluation we set the scaling factor “d” equal to 1 as this is the “assumed” value according to the guidance. Modifying the d value (or the  $R_3$  cut-off value) may improve the accuracy of the classifications.

Both regulatory agency guidance documents recommend mRNA as the endpoint for testing induction potential. Fahmi et al (2010) showed that the measurement of CYP3A4 mRNA was more sensitive in detecting induction in hepatocytes compared to enzyme activity, while both endpoints were found effective at classifying clinical induction response. Our results support a similar conclusion. In general, we selected compounds in our test set biased away from potent inhibitors of CYP3A4 enzyme, to avoid the potentially confounding effects of enzyme inhibition. Clotrimazole, which was shown to exhibit a  $K_i$  value for liver microsomal CYP3A4 of 0.25 nM (Gibbs et al, 1999), is the notable exception. In this case, metabolic depletion and/or the wash

## DMD #58602

steps conducted prior to testosterone addition likely precluded significant inhibition. Enzyme activity alone would probably have limited value as a predictor when examining compounds found to strongly or irreversibly inhibit enzyme activity within hepatocytes (e.g. ritonavir) as this may not always show a corresponding result *in vivo* (Kirby et al, 2011). Both midazolam (*in vivo* probe) and testosterone (*in vitro* probe) are substrates of CYP3A5 (Williams et al, 2003). This weakly inducible enzyme (Fahmi et al, 2010) exhibits polymorphic expression [(e.g. expressed in 10 to 30% of Caucasians and 50%-70% of African Americans (Daly, 2006)]. Whether clinical subject and hepatocyte donor CYP3A5 genotype status would help explain some variability in the models is not known.

Calculations of  $F_2$ ,  $RIS$ ,  $R_3$ , and  $C_{max}/EC_{50}$ , require preparation of a dose-response curve, ideally with sigmoidal shape and well-defined maxima and minima. While minima were reasonably well-defined, we noted that approximately 70% of compounds did not reach clear maxima, likely due to compound incomplete solubility, cytotoxicity, enzyme inhibition, or a combination thereof. In about 15% of the curves, a plateau was not reached because the concentration range was likely insufficient. For these cases, we deployed a strategy of constraining  $E_{max}$  to the observed maximal fold induction level that exhibited no evidence of insolubility or cytotoxicity; the  $EC_{50}$  parameter was then obtained from the curve fitting model. An alternative approach to not reaching well-defined maxima is to use the slope of the curve or  $AUC/F_2$  as predictors (Shou et al. 2008; Kanebratt and Andersson, 2008). Our data support the value of obtaining the  $AUC/F_2$  parameter.

In an *in vitro* induction assay, nominal and final (e.g. at the end of the treatment period), intracellular concentrations may differ and could impact model predictivity. Differences may be

## DMD #58602

attributable to cellular uptake, metabolic depletion, compound degradation, binding to cellular components or the plate or a combination of these. As recommended by the EMA guidance, we investigated drug concentrations in the medium on the last day of incubation. For eleven out of seventeen compounds, concentrations were within approximately 2-fold of nominal at the concentrations closest to the reported  $C_{\max-u}$ . However, six compounds exhibited concentrations < 20% of nominal (Supplemental Table 8), suggesting that intracellular unbound concentrations were substantially less than those used to derive  $EC_{50}$  and  $E_{\max}$ . When we used the time-weighted average concentrations to derive these parameters, in general,  $EC_{50}$  values were lower and  $E_{\max}$  values were unchanged. Somewhat surprisingly, this exercise showed no improvement on RMSE and GMFE for any parameter (results not shown).

In conclusion, *in vivo* CYP3A4 induction responses were well-predicted by the plated-hepatocyte model, using parameters  $RIS$ ,  $R_3$ ,  $C_{\max}/EC_{50}$ , and  $AUC/F_2$  in calibration-curve based models. Our data provide no strong basis for selecting a preferential model for predicting an induction response, although  $AUC/F_2$  was somewhat less accurate and exhibited higher prediction bias. Enzyme activity and mRNA were equally effective as endpoints. If only one endpoint can be generated, mRNA is preferred, due to the potential confounding effects of enzyme inhibition. However, we found examples (e.g. quinidine) where integrating results of both mRNA and enzyme activity could provide a higher level of confidence in the evaluation as compared to either endpoint alone. In a general evaluation scheme the development stage, considering the resources needed to construct calibration curves as well as the potential need for range-finding, we would suggest using a 3-donor screening test to first classify a potential inducer from a basic method (such as described in the EMA guidance), followed by the more comprehensive  $RIS$  testing in calibrated hepatocytes for those compounds exhibiting induction.

DMD #58602

## **Acknowledgements**

We thank Dr. Charles Crespi from Corning Life Sciences for reviewing the manuscript and for providing useful suggestions.

## **Authorship Contributions**

*Participated in Research design: Zhang and Stresser*

*Conducted experiments: Zhang, Ho, Callendrello, Clark, Santone, Xiao*

*Performed data analysis: Zhang, Stresser, Einolf, Kinsman*

*Wrote or contributed to the writing of the manuscript: Zhang, Stresser, Einolf, Fox*

DMD #58602

## References

- Adams M, Pieniaszek HJ Jr, Gammaitoni AR and Ahdieh H (2005) Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. *J Clin Pharmacol* **45**:337-345.
- Ahonen J, Olkkola KT and Neuvonen PJ (1995) Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. *Br J Clin Pharmacol* **40**:270-272.
- Almond LM, Yang J, Jamei M, Tucker GT, Rostami-Hodjegan A (2009) Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. *Curr Drug Metab* **10**:420-432.
- Backman JT, Olkkola KT and Neuvonen PJ (1996)<sup>a</sup> Rifampin drastically reduces plasma concentrations and effects of oral midazolam. *Clin Pharmacol Ther* **59**:7-13.
- Backman JT, Olkkola KT, Ojala M, Laaksovirta H and Neuvonen PJ (1996)<sup>b</sup> Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. *Epilepsia* **37**:253-257.
- Backman JT, Kivistö KT, Olkkola KT and Neuvonen PJ (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. *Eur J Clin Pharmacol* **54**:53-58.
- Daly AK (2006) Significance of the minor cytochrome P450 3A isoforms. *Clin Pharmacokinet* **45**:13-31.
- Eap CB, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A and Kerb R (2004) Oral administration of a low dose of midazolam (75 microg) as an *in vivo* probe for CYP3A activity. *Eur J Clin Pharmacol* **60**:237-246.

DMD #58602

Einolf HJ, Chen L, Fahmi OA, Gibson CR, Obach RS, Shebley M, Silva J, Sinz MW, Unadkat JD, Zhang L and Zhao P (2013) Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using *in vitro* CYP3A4 mRNA induction data. *Clin Pharmacol Ther* doi: 10.1038/clpt.2013.170.

European Medicine Agency (EMA) (2013) Guideline on the investigation of drug interactions (final).

[http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2012/07/WC500129606.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf).

Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R, Obach RS (2009) Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 *in vitro* data: predictions of compounds as precipitants of interaction. *Drug Metab Dispos* **37**:1658-1666.

Fahmi OA, Kish M, Boldt S and Obach RS (2010) Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes. *Drug Metab Dispos* **38**:1605-1611

Fahmi OA and Ripp SL (2011) Evaluation of models for predicting drug-drug interactions due to induction. *Expert Opin Drug Metab Toxicol* **6**:1399-1416.

Fahmi OA, Raucy JL, Ponce E, Hassanali S and Lasker JM (2012). Utility of DPX2 cells for predicting CYP3A induction-mediated drug-drug interactions and associated structure-activity relationships. *Drug Metab Dispos* **40**:2204-2211.

FDA (2012) Guidance for Industry- Drug interaction studies- study design, data analysis, implications for dosing, and labeling recommendations (draft guidance).

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance>



[s/ucm292362.pdf](#).

- Furukori H, Otani K, Yasui N, Kondo T, Kaneko S, Shimoyama R, Ohkubo T, Nagasaki T and Sugawara K (1998) Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. *Neuropsychopharmacology* **18**:364-369.
- Gibbs MA, Kunze KL, Howald WN, Thummel KE(1999) Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. *Drug Metab Dispos* **27**:596–599.
- Harris RZ, Inglis AM, Miller AK, Thompson KA, Finnerty D, Patterson S, Jorkasky DK and Freed MI (1999) Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics. *J Clin Pharmacol* **39**:1189-1194.
- Inglis AM, Miller AK, Culkin KT, Finnerty D, Patterson SD, Jorkasky DK and Freed MI (2001) Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. *J Clin Pharmacol* **41**:683-690.
- Isoherranen N, Lutz JD, Chung SP, Hachad H, Levy RH, Ragueneau-Majlessi I (2012) Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from *in vitro* data. *Chem Res Toxicol* **25**:2285-2300.
- Kanebratt KP and Andersson TB (2008) HepaRG cells as an *in vitro* model for evaluation of cytochrome P450 induction in humans. *Drug Metab Dispos* **36**:137-145.
- Kato M, Chiba K, Horikawa M, Sugiyama Y (2005). The quantitative prediction of *in vivo* enzyme-induction caused by drug exposure from *in vitro* information on human hepatocytes. *Drug Metab Pharmacokinet* **20**:236-243.
- Kim KA, Oh SO, Park PW and Park JY (2005) Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. *Eur J Clin Pharmacol* **61**:275-280.

Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE and Unadkat JD (2011)

Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. *Drug Metab Dispos* **39**:1070-1078.

Leizorovicz A, Piolat C, Boissel JP, Sanchini B and Ferry S (1984) Comparison of two long-acting forms of quinidine. *Br J Clin Pharmacol* **17**:729-734.

Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta CT}$  method. *Methods* **25**: 402-408.

Ma JD, Nafziger AN, Rhodes G, Liu S and Bertino JS (2006) Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. *Drug Metab Dispos.* **34**:783-785.

McGinnity DF, Zhang G, Kenny JR, Hamilton GA, Otmani S, Stams KR, Haney S, Brassil P, Stresser DM and Riley RJ (2009) Evaluation of multiple *in vitro* systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. *Drug Metab Dispos* **37**:1259-1268.

Mihaly GW, Ching MS, Klejn MB, Paull J and Smallwood RA (1987) Differences in the binding of quinine and quinidine to plasma proteins. *Br J Clin Pharmacol* **24**:769-774.

Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, Ishiguro N, Kishimoto W, Ludwig-Schwellinger E, Ebner T, et al.(2012) Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. *Drug Metab Dispos* **40**:83–92.

O'Reilly RA (1982) Stereoselective interaction of sulfinpyrazone with racemic warfarin and its

separated enantiomorphs in man. *Circulation* **65**:202-207.

- Prueksaritanont T, Vega JM, Zhao J, Gagliano K, Kuznetsova O, Musser B, Amin RD, Liu L, Roadcap BA, Dilzer S, Lasseter KC and Rogers JD (2001) Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. *J Clin Pharmacol* **41**:573-581.
- Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS, de Morais SM (2006) Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. *Drug Metab Dispos* **34**:1742-1748.
- Schellens JH, van der Wart JH, Brugman M and Breimer DD (1989) Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephentyoin and antipyrine in humans as assessed by a "cocktail" study design. *J Pharmacol Exp Ther*. **249**:638-645.
- Selen A, Amidon GL and Welling PG (1982) Pharmacokinetics of probenecid following oral doses to human volunteers. *J Pharm Sci* **71**:1238-1242.
- Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther* **270**:414-423.
- Shord SS, Chan LN, Camp JR, Vasquez EM, Jeong HY, Molokie RE, Baum CL and Xie H (2010) Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. *Br J Clin Pharmacol* **69**:160-166.
- Shou M, Hayashi M, Pan Y, Xu Y, Morrissey K, Xu L, Skiles GL (2008) Modeling, prediction, and *in vitro in vivo* correlation of CYP3A4 induction. *Drug Metab Dispos* **36**:2355-2370.
- Soons PA, van den Berg G, Danhof M, van Brummelen P, Jansen JB, Lamers CB and Breimer DD (1992) Influence of single- and multiple-dose omeprazole treatment on nifedipine

DMD #58602

pharmacokinetics and effects in healthy subjects. *Eur J Clin Pharmacol* **42**:319-324.

Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. *Nat Rev Drug Discov* **4**:825-833

Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA(2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. *Drug Metab Dispos* **30**:883–891

Xu Y, Zhou Y, Hayashi M, Shou M, Skiles GL (2011) Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs. *Drug Metab Dispos* **39**:1139-1148.

Zhang JG, Ho T, Callendrello AL, Crespi CL and Stresser DM (2010). A multi-endpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocyte cultures after treatment with  $\beta$ -naphthoflavone, phenobarbital and rifampicin. *Drug Metab Lett* **4**:185-194.

DMD #58602

## Footnotes

Parts of the work were presented at the International Society for the Study of Xenobiotics (ISSX) 18<sup>th</sup> North American Regional Meeting, Oct. 14-18, 2012, Dallas, Texas and 10<sup>th</sup> international ISSX meeting, Sep. 29-Oct. 3, 2013, Toronto, Canada.

## Figure Legends

**Fig. 1.** Calibration curve of midazolam AUC change (%) as a function of RIS, obtained from induction data for CYP3A4 mRNA (A, based on  $C_{\max-t}$ ; B, based on  $C_{\max-u}$ ) and testosterone 6 $\beta$ -hydroxylase activity (C, based on  $C_{\max-t}$ ; D, based on  $C_{\max-u}$ ) in lot 295 human hepatocytes. The RIS values were calculated based on both total and unbound  $C_{\max}$ . The interacting drugs used for the curve fitting are shown in Table 3. See supplement data for lots 312 and 318.

**Fig. 2.** Calibration curve of midazolam AUC change (%) as a function of  $R_3$ , obtained from induction data for CYP3A4 mRNA (A, based on  $C_{\max-t}$ ; B, based on  $C_{\max-u}$ ) and testosterone 6 $\beta$ -hydroxylase activity (C, based on  $C_{\max-t}$ ; D, based on  $C_{\max-u}$ ) in Lot 295 human hepatocytes. The  $R_3$  values were calculated based on both total and unbound  $C_{\max}$ . The interacting drugs used for the curve fitting are shown in Table 3. See supplement data for lots 312 and 318.

**Fig. 3.** Calibration curve of midazolam AUC change (%) as a function of  $C_{\max}/EC_{50}$ , obtained from induction data for CYP3A4 mRNA (A, based on  $C_{\max-t}$ ; B, based on  $C_{\max-u}$ ) and testosterone 6 $\beta$ -hydroxylase activity (C, based on  $C_{\max-t}$ ; D, based on  $C_{\max-u}$ ) in Lot 295 human hepatocytes. The  $C_{\max}/EC_{50}$  values were calculated based on both total and unbound  $C_{\max}$ . The interacting drugs used for the curve fitting are shown in Table 3. See supplement data for lots 312 and 318.

**Fig. 4.** Calibration curve of observed midazolam AUC change (%) as a function of  $AUC/F_2$ , obtained from induction data for CYP3A4 mRNA (A) and testosterone 6 $\beta$ -hydroxylase

DMD #58602

activity (B) in Lot 295 human hepatocytes. The interacting drugs used for the curve fitting are shown in Table 3. See supplemental data for lots 312 and 318.

**Fig. 5.** Correlation analysis of observed midazolam and non-midazolam AUC change (%) and predicted AUC changed (%) from RIS (A, based on  $C_{\max-t}$ ; B, based on  $C_{\max-u}$ ),  $R_3$  (C, based on  $C_{\max-t}$ ; D, based on  $C_{\max-u}$ ), and  $C_{\max}/EC_{50}$  (E, based on  $C_{\max-t}$ ; F, based on  $C_{\max-u}$ ) derived from CYP3A4 mRNA for three lots of human hepatocytes. Solid black line represents unity. Dashed lines represent the boundary denoting predicted changes within  $\pm 20\%$  of observed. The data points outside of these lines were considered either under- or over-predicted.

**Fig. 6.** Correlation analysis of observed midazolam and non-midazolam AUC change (%) and predicted AUC changed (%) from RIS (A, based on  $C_{\max-t}$ ; B, based on  $C_{\max-u}$ ),  $R_3$  (C, based on  $C_{\max-t}$ ; D, based on  $C_{\max-u}$ ), and  $C_{\max}/EC_{50}$  (E, based on  $C_{\max-t}$ ; F, based on  $C_{\max-u}$ ) derived from CYP3A4 enzyme activity for three lots of human hepatocytes. Solid black line represents unity. Dashed lines represent the boundary denoting predicted changes within  $\pm 20\%$  of observed. The data points outside of these lines were considered either under- or over-predicted.

**Fig. 7.** Correlation analysis of observed midazolam and non-midazolam AUC change (%) and predicted AUC changed (%) from AUC/ $F_2$  derived from CYP3A4 mRNA (A) and enzyme activity (B) for three lots of human hepatocytes. Solid black line represents unity. Dashed lines represent the boundary denoting predicted changes within  $\pm 20\%$  of observed. The data points outside of these lines were considered either under- or over-

DMD #58602

predicted.

**Fig. 8.** Correlation analysis of observed midazolam and non-midazolam AUC change (%) and % of positive control response, derived from CYP3A4 mRNA and enzyme activity for three lots of human hepatocytes.



TABLE 1 EC<sub>50</sub>, E<sub>max</sub>, F<sub>2</sub>, and % of positive control rifampicin response (% PC) obtained with CYP3A4 mRNA expression induction data from three lots of human hepatocytes

| Test Drug      | Test Concentration<br>Range (μM) | Lot 295                  |                            |                        |      | Lot 312                  |                            |                        |      | Lot 318                  |                            |                        |      |
|----------------|----------------------------------|--------------------------|----------------------------|------------------------|------|--------------------------|----------------------------|------------------------|------|--------------------------|----------------------------|------------------------|------|
|                |                                  | EC <sub>50</sub><br>(μM) | E <sub>max</sub><br>(Fold) | F <sub>2</sub><br>(μM) | % PC | EC <sub>50</sub><br>(μM) | E <sub>max</sub><br>(Fold) | F <sub>2</sub><br>(μM) | % PC | EC <sub>50</sub><br>(μM) | E <sub>max</sub><br>(Fold) | F <sub>2</sub><br>(μM) | % PC |
| Rifampicin     | 0.01-50                          | 0.12                     | 7.3                        | 0.046                  | 100  | 1.4                      | 16                         | 0.20                   | 100  | 0.44                     | 7.4                        | 0.11                   | 100  |
| Phenytoin      | 0.23-500                         | 14                       | 3.6                        | 7.9                    | 40   | 13                       | 4.6                        | 12                     | 23   | 9.5                      | 4.1                        | 8.3                    | 44   |
| Carbamazepine  | 0.23-500                         | 17                       | 4.4                        | 13                     | 52   | 27                       | 6.4                        | 9.3                    | 28   | 4.3                      | 14                         | 2.5                    | 218  |
| Phenobarbital  | 0.91-2000                        | 237                      | 7.2                        | 116                    | 96   | 83                       | 6.1                        | 14                     | 34   | 138                      | 8.3                        | 78                     | 106  |
| Troglitazone   | 0.03-20                          | 4.4                      | 10                         | 0.75                   | 139  | 1.0                      | 3.7                        | 0.48                   | 20   | 5.7                      | 5.1                        | 3.2                    | 59   |
| Terbinafine    | 0.05-100                         | 2.6                      | 3.4                        | 1.3                    | 39   | 2.2                      | 3.1                        | 1.3                    | 14   | 8.6                      | 2.8                        | 6.3                    | 27   |
| Pleconaril     | 0.05-100                         | 2.9                      | 1.4                        | 18                     | 6    | 3.4                      | 3.0                        | 2.7                    | 13   | 6.4                      | 1.9                        | 11                     | 12   |
| Sulfinpyrazone | 0.09-200                         | 13                       | 14                         | 3.1                    | 186  | 28                       | 19                         | 3.1                    | 119  | 8.2                      | 5.8                        | 3.1                    | 69   |
| Probenecid     | 0.05-300                         | 39                       | 4.6                        | 32                     | 56   | 123                      | 9.2                        | 78                     | 55   | 77                       | 6.6                        | 29                     | 80   |
| Pioglitazone   | 0.05-100                         | 2.9                      | 1.8                        | 4.1                    | 13   | 3.9                      | 3.5                        | 3.3                    | 17   | 3.5                      | 3.2                        | 3.2                    | 31   |
| Dexamethasone  | 0.11-250                         | 31                       | 8.4                        | 18                     | 114  | 22                       | 7.4                        | 14                     | 44   | 25                       | 3.8                        | 15                     | 41   |
| Rosiglitazone  | 0.05-100                         | 8.5                      | 4.1                        | 3.4                    | 47   | 7.8                      | 7.5                        | 2.7                    | 44   | 10                       | 7.3                        | 5.0                    | 90   |
| Omeprazole     | 0.05-100                         | 8.0                      | 1.9                        | 6.5                    | 13   | 4.8                      | 2.8                        | 3.5                    | 12   | NA <sup>1</sup>          | 2.2                        | NA                     | 17   |
| Clotrimazole   | 0.005-10                         | 3.3                      | 7.8                        | 1.6                    | 104  | 2.6                      | 6.3                        | 1.1                    | 36   | 4.1                      | 5.3                        | 3.5                    | 62   |

DMD #58602

|              |            |     |     |     |     |    |     |      |    |     |     |     |    |
|--------------|------------|-----|-----|-----|-----|----|-----|------|----|-----|-----|-----|----|
| Nifedipine   | 0.05-100   | 8.0 | 7.7 | 3.2 | 104 | 13 | 5.7 | 8.8  | 32 | 6.3 | 3.3 | 4.4 | 33 |
| Flumazenil   | 0.023-50   | NI  | NI  | 22  | NA  | 23 | 2.5 | 25   | 10 | NI  | NI  | NI  | NI |
| Quinidine    | 0.11-250   | 11  | 1.5 | 11  | 7   | 15 | 6.9 | 8.04 | 31 | NA  | NA  | NA  | 24 |
| Primaquine   | 0.04-40    | NI  | NI  | NI  | NI  | NI | NI  | NI   | NI | NI  | NI  | NI  | NI |
| Methotrexate | 0.2-20     | NI  | NI  | NI  | NI  | NI | NI  | NI   | NI | NI  | NI  | NI  | NI |
| Digoxin      | 0.0002-0.2 | NI  | NI  | NI  | NI  | NI | NI  | NI   | NI | NI  | NI  | NI  | NI |

<sup>1</sup> - NA - not applicable; insufficient response for a reliable estimate; NI - no induction was found at the concentrations tested.

TABLE 2 EC<sub>50</sub>, E<sub>max</sub>, F<sub>2</sub>, and % of positive control rifampicin response (% PC) obtained with CYP3A4-mediated testosterone 6β-hydroxylation induction data from three lots of human hepatocytes

| Test Drug      | Test Concentration<br>Range (μM) | Lot 295                  |                            |                        |      | Lot 312                  |                            |                        |      | Lot 318                  |                            |                        |      |
|----------------|----------------------------------|--------------------------|----------------------------|------------------------|------|--------------------------|----------------------------|------------------------|------|--------------------------|----------------------------|------------------------|------|
|                |                                  | EC <sub>50</sub><br>(μM) | E <sub>max</sub><br>(Fold) | F <sub>2</sub><br>(μM) | % PC | EC <sub>50</sub><br>(μM) | E <sub>max</sub><br>(Fold) | F <sub>2</sub><br>(μM) | % PC | EC <sub>50</sub><br>(μM) | E <sub>max</sub><br>(Fold) | F <sub>2</sub><br>(μM) | % PC |
| Rifampicin     | 0.01-50                          | 0.18                     | 5.9                        | 0.011                  | 100  | 1.1                      | 8.9                        | 0                      | 100  | 0.65                     | 3.2                        | 0.20                   | 100  |
| Phenytoin      | 0.23-500                         | 9.9                      | 2.6                        | 8.0                    | 34   | 10                       | 3.2                        | 9.8                    | 28   | 6.7                      | 1.9                        | 18                     | 47   |
| Carbamazepine  | 0.23-500                         | 22                       | 2.6                        | 21                     | 30   | 15                       | 2.8                        | 18                     | 26   | 5.5                      | 1.9                        | 8.8                    | 50   |
| Phenobarbital  | 0.91-2000                        | 153                      | 4.0                        | 91                     | 63   | 195                      | 4.8                        | 117                    | 49   | 106                      | 2.0                        | 511                    | 52   |
| Troglitazone   | 0.03-20                          | 1.3                      | 2.7                        | 1.4                    | 36   | 1.4                      | 2.7                        | 1.2                    | 22   | 1.2                      | 1.8                        | 6.0                    | 40   |
| Terbinafine    | 0.05-100                         | 3.2                      | 2.9                        | 2.9                    | 39   | 4.6                      | 3.8                        | 2.9                    | 35   | 4.8                      | 1.6                        | 9.3                    | 46   |
| Pleconaril     | 0.05-100                         | 4.0                      | 1.6                        | NA <sup>1</sup>        | 13   | 4.0                      | 2.0                        | 7.4                    | 13   | 3.7                      | 1.5                        | NA                     | 26   |
| Sulfinpyrazone | 0.09-200                         | 7.5                      | 3.3                        | 7.4                    | 55   | 8.2                      | 3.5                        | 7.8                    | 34   | 4.9                      | 2.2                        | 9.4                    | 63   |
| Probenecid     | 0.05-300                         | 39                       | 2.6                        | 42                     | 33   | 90                       | 3.0                        | 65                     | 26   | 36                       | 1.7                        | NA                     | 35   |
| Pioglitazone   | 0.05-100                         | 2.7                      | 2.4                        | 3.3                    | 24   | 4.2                      | 2.5                        | 5.2                    | 19   | 2.9                      | 1.6                        | NA                     | 31   |
| Dexamethasone  | 0.11-250                         | 18                       | 3.3                        | 15                     | 48   | 20                       | 3.9                        | 16                     | 37   | 17                       | 2.3                        | 34                     | 70   |
| Rosiglitazone  | 0.05-100                         | 7.5                      | 3.7                        | 5.0                    | 57   | 11                       | 6.3                        | 6.4                    | 67   | 8.0                      | 2.9                        | 11                     | 98   |
| Omeprazole     | 0.05-100                         | 3.8                      | 1.5                        | NA                     | 11   | 2.4                      | 1.4                        | NA                     | 6    | 1.2                      | 1.4                        | NA                     | 23   |
| Clotrimazole   | 0.005-10                         | 1.1                      | 3.3                        | 0.99                   | 47   | 1.0                      | 3.1                        | 1.0                    | 26   | NA                       | NA                         | NA                     | 5    |

DMD #58602

|              |            |     |     |     |    |     |     |     |    |     |     |    |    |
|--------------|------------|-----|-----|-----|----|-----|-----|-----|----|-----|-----|----|----|
| Nifedipine   | 0.05-100   | 3.2 | 3.0 | 2.7 | 41 | 4.5 | 2.3 | 5.2 | 17 | 6.5 | 1.4 | NA | 20 |
| Flumazenil   | 0.023-50   | NI  | NI  | NI  | NI | NA  | 1.4 | NA  | 5  | NI  | NI  | NI | NI |
| Quinidine    | 0.11-250   | NI  | NI  | NI  | NI | NI  | NI  | NI  | NI | NI  | NI  | NI | NI |
| Primaquine   | 0.04-40    | NI  | NI  | NI  | NI | NI  | NI  | NI  | NI | NI  | NI  | NI | NI |
| Methotrexate | 0.2-20     | NI  | NI  | NI  | NI | NI  | NI  | NI  | NI | NI  | NI  | NI | NI |
| Digoxin      | 0.0002-0.2 | NI  | NI  | NI  | NI | NI  | NI  | NI  | NI | NI  | NI  | NI | NI |

<sup>1</sup> - NA - not applicable; insufficient response for a reliable estimate; NI - no induction was found at the concentrations tested.

TABLE 3 Clinical pharmacokinetic and drug-drug interaction data

| Category of Clinical             | Interacting Drug         | C <sub>max-t</sub> (µM) | C <sub>max-u</sub> (µM) | AUC (h. µM) | Victim Drug | Observed AUC Change | References  |
|----------------------------------|--------------------------|-------------------------|-------------------------|-------------|-------------|---------------------|---|
| Strong, ≥80% decrease in AUC     | Rifampicin* <sup>l</sup> | 15                      | 3.6                     | 34          | midazolam   | 98                  | Backman et al., 1998; Kanebratt and Anderson, 2008                            |
|                                  | Rifampicin*              | 11                      | 2.7                     | 34          | midazolam   | 95                  | Eap et al., 2004  |
|                                  | Rifampicin*              | 10                      | 2.5                     | 34          | midazolam   | 97                  | Fahmi et al., 2012; Backman et al., 1996 <sup>a</sup>                         |
|                                  | Rifampicin*              | 6.5                     | 1.6                     | 34          | midazolam   | 86                  | Adams et al., 2005  |
|                                  | Phenytoin*               | 29                      | 7.3                     | 468         | midazolam   | 94                  | Backman et al., 1996 <sup>b</sup> ; Kanebratt and Anderson, 2008              |
|                                  | Carbamazepine*           | 21                      | 5.3                     | 1248        | midazolam   | 94                  | Backman et al., 1996 <sup>b</sup> ; Kanebratt and Anderson, 2008              |
|                                  | Carbamazepine            | 25                      | 6.1                     | 1248        | alprazolam  | 58                  | Furukori et al., 1998   |
| Moderate, 50-80% decrease in AUC | Phenobarbital            | 56                      | 28                      | 1497        | nifedipine  | 61                  | Schellens et al., 1989, Kanebratt and Anderson, 2008                          |
|                                  | Troglitazone             | 3.1                     | 0.031                   | 24          | simvastatin | 38                  | Fahmi et al., 2012, Prueksaritanont et al, 2001, Kanebratt and Anderson, 2008 |
|                                  | Troglitazone*            | 6.3                     | 0.063                   | 50          | midazolam   | 67                  | Fahmi et al., 2012  |
| Weak, 20-50% decrease in AUC     | Terbinafine*             | 2.4                     | 0.024                   | 16          | midazolam   | 25                  | Ahonen, et al., 1995  |
|                                  | Pleconaril*              | 3.0                     | 0.030                   | 42          | midazolam   | 35                  | Ma, et al., 2006; Fahmi and Ripp, 2010  |
|                                  | Pioglitazone             | 4.5                     | 0.045                   | 44          | simvastatin | -1                  | Prueksaritanont et al., 2001; Fahmi and Ripp, 2011                            |
|                                  | Pioglitazone*            | 2.8                     | 0.028                   | 44          | midazolam   | 26                  | Fahmi et al., 2012  |

DMD #58602

|                      |                |        |        |                 |                  |     |  |
|----------------------|----------------|--------|--------|-----------------|------------------|-----|--|
|                      | Sulfinpyrazone | 48     | 0.96   | 287             | R-warfarin       | 22  | O'Reilly, 1982; Kanebratt and Andersson,2008                 |
|                      | Probenecid     | 244    | 24     | 2705            | carbamazepine    | 20  | Kim et al.,2005; Selen et al., 1982                          |
| Clinical non-inducer | Dexamethasone  | 0.021  | 0.0054 | 0.29            | triazolam        | 19  | Fahmi et al., 2012, Kanebratt and Andersson, 2008            |
|                      | Nifedipine*    | 0.40   | 0.020  | 0.87            | midazolam        | 4   | Fahmi et al., 2012, Kanebratt and Andersson, 2008            |
|                      | Rosiglitazone  | 1.7    | 0.0033 | 8.2             | nifedipine       | 12  | Fahmi et al., 2012, Harris et al.,1999; Fahmi and Ripp, 2011 |
|                      | Rosiglitazone  | 1.4    | 0.0028 | 8.2             | ethinylestradiol | -1  | Inglis A et al., 2001; Fahmi and Ripp, 2011                  |
|                      | Omeprazole     | 0.74   | 0.037  | 1.1             | nifedipine       | -25 | Soons, et al., 1992; Kanebratt and Andersson, 2008           |
|                      | Clotrimazole*  | 0.0074 | 0.0001 | NA <sup>2</sup> | midazolam        | 9.7 | Shord et al., 2010   |
|                      | Flumazenil     | 0.0010 | 0.0005 | 0.050           | midazolam        | -2  | Fahmi et al., 2012   |
|                      | Quinidine      | 3.3    | 0.41   | 42              | NA               | 0   | Mihaly et al.,1987; Leizorovicz et al., 1984                 |

<sup>1</sup> – Interacting drugs marked with an asterisk were used for preparation of calibration curves. <sup>2</sup> – NA, clinical induction interaction data not available.

DMD #58602

TABLE 4 Summary of cut-off values, confidence interval (CI), and correlation coefficients ( $R^2$ ) of calibration curves for RIS,  $R_3$ ,  $C_{\max}/EC_{50}$ , and AUC/ $F_2$

| Hepatocyte<br>Lot No | Parameters    | RIS          |               | $R_3$        |              | $C_{\max}/EC_{50}$ |               | AUC/ $F_2$ |
|----------------------|---------------|--------------|---------------|--------------|--------------|--------------------|---------------|------------|
|                      |               | $C_{\max-t}$ | $C_{\max-u}$  | $C_{\max-t}$ | $C_{\max-u}$ | $C_{\max-t}$       | $C_{\max-u}$  |            |
| <b>mRNA Data</b>     |               |              |               |              |              |                    |               |            |
| Lot 295              | Cut-off value | <b>0.74</b>  | <b>0.017</b>  | <b>0.57</b>  | <b>0.98</b>  | <b>0.94</b>        | <b>0.0088</b> | <b>6.2</b> |
|                      | 95% CI        | 0.54         | 0.013         | 0.20         | 0.029        | 0.079              | 0.00084       | 7.0        |
|                      | $R^2$         | 0.91         | 0.97          | 0.91         | 0.98         | 0.97               | 0.995         | 0.94       |
| Lot 312              | Cut-off value | <b>1.32</b>  | <b>0.019</b>  | <b>0.44</b>  | <b>0.98</b>  | <b>0.23</b>        | <b>0.0056</b> | <b>12</b>  |
|                      | 95% CI        | 0.28         | 0.0093        | 0.062        | 0.037        | 0.46               | 0.0028        | 3.4        |
|                      | $R^2$         | 0.97         | 0.99          | 0.97         | 0.98         | 0.84               | 0.99          | 0.97       |
| Lot 318              | Cut-off value | <b>0.62</b>  | <b>0.011</b>  | <b>0.62</b>  | <b>0.99</b>  | <b>0.33</b>        | <b>0.0038</b> | <b>2.3</b> |
|                      | 95% CI        | 0.35         | 0.011         | 0.18         | 0.014        | 0.21               | 0.0021        | 2.6        |
|                      | $R^2$         | 0.96         | 0.96          | 0.97         | 0.97         | 0.97               | 0.97          | 0.95       |
| <b>Activity Data</b> |               |              |               |              |              |                    |               |            |
| Lot 295              | Cut-off value | <b>0.60</b>  | <b>0.017</b>  | <b>0.63</b>  | <b>0.98</b>  | <b>0.62</b>        | <b>0.0069</b> | <b>8.8</b> |
|                      | 95% CI        | 0.63         | 0.011         | 0.28         | 0.026        | 0.43               | 0.0034        | 5.4        |
|                      | $R^2$         | 0.87         | 0.97          | 0.87         | 0.98         | 0.88               | 0.98          | 0.98       |
| Lot 312              | Cut-off value | <b>0.84</b>  | <b>0.013</b>  | <b>0.56</b>  | <b>0.99</b>  | <b>0.58</b>        | <b>0.005</b>  | <b>4.4</b> |
|                      | 95% CI        | 0.37         | 0.0069        | 0.13         | 0.023        | 0.15               | 0.0025        | 2.7        |
|                      | $R^2$         | 0.93         | 0.98          | 0.93         | 0.98         | 0.97               | 0.99          | 0.97       |
| Lot 318              | Cut-off value | <b>0.57</b>  | <b>0.0078</b> | <b>0.65</b>  | <b>0.995</b> | <b>0.53</b>        | <b>0.0052</b> | <b>1.0</b> |
|                      | 95% CI        | 0.18         | 0.0039        | 0.084        | 0.020        | 0.34               | 0.0025        | 3.2        |
|                      | $R^2$         | 0.97         | 0.99          | 0.97         | 0.98         | 0.96               | 0.99          | 0.78       |

RIS,  $R_3$ ,  $C_{\max}/EC_{50}$  were calculated using both  $C_{\max-t}$  and  $C_{\max-u}$ . Cut-off values for RIS,  $R_3$ ,  $C_{\max}/EC_{50}$  and AUC/ $F_2$

were defined as that corresponding to 20% predicted AUC change.

TABLE 5  $R_3$  values calculated based on total and unbound  $C_{max}$  for induction response of CYP3A4 mRNA and enzyme activity in three lots of human hepatocytes

| Category of<br>Clinical<br>Inducer        | Interacting Drug | Lot 295        |          |                         |             | Lot 312        |          |                |             | Lot 318        |          |                |             |
|---|------------------|----------------|----------|-------------------------|-------------|----------------|----------|----------------|-------------|----------------|----------|----------------|-------------|
|   |                  | $R_{3-Cmax-t}$ |          | $R_{3-Cmax-u}$          |             | $R_{3-Cmax-t}$ |          | $R_{3-Cmax-u}$ |             | $R_{3-Cmax-t}$ |          | $R_{3-Cmax-u}$ |             |
|   |                  | mRNA           | Activity | mRNA                    | Activity    | mRNA           | Activity | mRNA           | Activity    | mRNA           | Activity | mRNA           | Activity    |
| Strong, $\geq 80\%$<br>decrease in<br>AUC | Rifampicin       | 0.12           | 0.15     | 0.12                    | 0.15        | 0.065          | 0.11     | 0.080          | 0.13        | 0.12           | 0.25     | 0.13           | 0.27        |
|   | Rifampicin       | 0.12           | 0.15     | 0.12                    | 0.15        | 0.067          | 0.11     | 0.087          | 0.14        | 0.12           | 0.25     | 0.13           | 0.28        |
|   | Rifampicin       | 0.12           | 0.15     | 0.13                    | 0.15        | 0.067          | 0.11     | 0.089          | 0.14        | 0.12           | 0.25     | 0.14           | 0.29        |
|   | Rifampicin       | 0.12           | 0.15     | 0.13                    | 0.16        | 0.071          | 0.12     | 0.10           | 0.16        | 0.13           | 0.26     | 0.15           | 0.31        |
|   | Phenytoin        | 0.29           | 0.34     | 0.45                    | 0.48        | 0.24           | 0.30     | 0.38           | 0.43        | 0.25           | 0.40     | 0.36           | 0.51        |
|   | Carbamazepine    | 0.29           | 0.44     | 0.50                    | 0.67        | 0.26           | 0.38     | 0.49           | 0.58        | 0.082          | 0.40     | 0.12           | 0.52        |
|   | Carbamazepine    | 0.28           | 0.42     | 0.47                    | 0.64        | 0.25           | 0.37     | 0.46           | 0.55        | 0.080          | 0.39     | 0.11           | 0.50        |
| Moderate, 50-<br>80% decrease<br>in AUC   | Phenobarbital    | 0.42           | 0.48     | 0.57                    | 0.62        | 0.29           | 0.48     | 0.40           | 0.63        | 0.29           | 0.59     | 0.42           | 0.71        |
|   | Troglitazone     | 0.20           | 0.34     | <b>0.93<sup>l</sup></b> | <b>0.94</b> | 0.27           | 0.34     | <b>0.90</b>    | <b>0.94</b> | 0.36           | 0.44     | <b>0.97</b>    | <b>0.96</b> |
|   | Troglitazone     | 0.15           | 0.31     | 0.88                    | 0.89        | 0.24           | 0.31     | 0.83           | 0.89        | 0.27           | 0.40     | <b>0.95</b>    | <b>0.92</b> |
| Weak, 20-<br>50% decrease                 | Terbinafine      | 0.38           | 0.45     | <b>0.97</b>             | <b>0.98</b> | 0.38           | 0.43     | <b>0.97</b>    | <b>0.98</b> | 0.62           | 0.65     | <b>0.99</b>    | <b>0.99</b> |
|   | Pleconaril       | 0.59           | 0.59     | <b>0.99</b>             | <b>0.99</b> | 0.42           | 0.54     | <b>0.97</b>    | <b>0.99</b> | 0.63           | 0.60     | <b>0.99</b>    | <b>0.99</b> |
|   | Pioglitazone     | 0.47           | 0.40     | <b>0.97</b>             | <b>0.96</b> | 0.35           | 0.44     | <b>0.96</b>    | <b>0.97</b> | 0.36           | 0.51     | <b>0.96</b>    | <b>0.98</b> |



DMD #58602

|                      |                |             |             |             |             |             |             |             |             |             |             |             |             |
|----------------------|----------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| in AUC               | Pioglitazone   | 0.52        | 0.45        | <b>0.98</b> | <b>0.98</b> | 0.41        | 0.50        | <b>0.98</b> | <b>0.98</b> | 0.42        | 0.56        | <b>0.98</b> | <b>0.98</b> |
|                      | Sulfinpyrazone | 0.080       | 0.26        | 0.51        | 0.73        | 0.078       | 0.25        | 0.61        | 0.73        | 0.17        | 0.34        | 0.62        | 0.74        |
|                      | Probenecid     | 0.20        | 0.31        | 0.36        | 0.50        | 0.14        | 0.31        | 0.40        | 0.61        | 0.17        | 0.41        | 0.39        | 0.60        |
| Clinical non-inducer | Dexamethasone  | 0.99        | 1.00        | 1.0         | 1.0         | 0.99        | 1.0         | 1.0         | 1.0         | 1.0         | 1.0         | 1.0         | 1.0         |
|                      | Nifedipine     | <b>0.73</b> | <b>0.75</b> | 0.98        | 0.98        | <b>0.85</b> | <b>0.84</b> | 0.99        | 1.0         | <b>0.76</b> | 0.93        | 0.98        | 1.0         |
|                      | Rosiglitazone  | <b>0.60</b> | <b>0.60</b> | 1.0         | 1.0         | <b>0.43</b> | <b>0.54</b> | 1.0         | 1.0         | <b>0.50</b> | <b>0.67</b> | 1.0         | 1.0         |
|                      | Rosiglitazone  | <b>0.64</b> | <b>0.63</b> | 1.0         | 1.0         | <b>0.47</b> | <b>0.58</b> | 1.0         | 1.0         | <b>0.54</b> | <b>0.70</b> | 1.0         | 1.0         |
|                      | Omeprazole     | <b>0.86</b> | <b>0.81</b> | 0.99        | 0.99        | <b>0.73</b> | 0.75        | 0.98        | NA          | NA          | 0.64        | NA          | 1.0         |
|                      | Clotrimazole   | 0.98        | 0.98        | 1.0         | 1.0         | 0.98        | 0.98        | 1.0         | 0.99        | 0.99        | NA          | 1.0         | NA          |
|                      | Flumazenil     | NA          | NA          | NA          | NA          | 1.0         | NA          | 1.0         | NA          | NA          | NA          | NA          | NA          |
| Quinidine            | <b>0.75</b>    | NA          | 0.95        | NA          | <b>0.44</b> | NA          | <b>0.84</b> | NA          | NA          | NA          | NA          | NA          |             |

<sup>1</sup>- Values in bold were either over- or under-predicted based on the 0.9 cut-off value provided in the 2012 FDA draft guidance.


DMD #58602

TABLE 6 Accuracy and bias in the prediction of clinical CYP3A induction of midazolam and non-midazolam CYP3A substrates using the calibration-curve based approaches


| Methods  | Midazolam as a victim drug |       | Non-midazolam as a victim drug |       |
|--|----------------------------|-------|--------------------------------|-------|
|  | GMFE                       | RMSE  | GMFE                           | RMSE  |
| <b>Based on Total C<sub>max</sub> and mRNA Data</b>        |                            |       |                                |       |
| RIS  | 1.78                       | 0.120 | 2.25                           | 0.394 |
| R <sub>3</sub>   | 1.75                       | 0.115 | 2.33                           | 0.396 |
| C <sub>max</sub> /EC <sub>50</sub>                         | 1.73                       | 0.137 | 2.10                           | 0.414 |
| <b>Based on Total C<sub>max</sub> with Activity Data</b>   |                            |       |                                |       |
| RIS  | 1.78                       | 0.141 | 1.95                           | 0.391 |
| R <sub>3</sub>   | 1.79                       | 0.138 | 2.02                           | 0.398 |
| C <sub>max</sub> /EC <sub>50</sub>                         | 1.82                       | 0.126 | 2.50                           | 0.469 |
| <b>Based on Unbound C<sub>max</sub> with mRNA Data</b>     |                            |       |                                |       |
| RIS  | 1.40                       | 0.087 | 2.42                           | 0.405 |
| R <sub>3</sub>   | 1.34                       | 0.077 | 2.74                           | 0.412 |
| C <sub>max</sub> /EC <sub>50</sub>                         | 1.34                       | 0.065 | 2.65                           | 0.434 |
| <b>Based on Unbound C<sub>max</sub> with Activity Data</b> |                            |       |                                |       |
| RIS  | 1.37                       | 0.071 | 2.32                           | 0.409 |
| R <sub>3</sub>   | 1.34                       | 0.071 | 2.78                           | 0.415 |
| C <sub>max</sub> /EC <sub>50</sub>                         | 1.35                       | 0.062 | 2.30                           | 0.399 |
| <b>Based on AUC/F<sub>2</sub></b>                          |                            |       |                                |       |
| mRNA   | 1.70                       | 0.105 | 1.82                           | 0.326 |
| Activity   | 1.76                       | 0.117 | 1.67                           | 0.315 |

The predicted fold changes in AUC from all three hepatocyte lots were used in the calculations.


**Figure 1**



**Figure 2**



**Figure 3**



**Figure 4**




Figure 5






Figure 6





**Figure 7**



**Figure 8**

